Synagis 50 mg/0.5 ml solution for injection clinical trials

Randomized, multicenter, open-label study on PREvention of respiratory SEquelae of RSV bronchiolitis in preterm babies (PRESERV)

This study looks at how to help premature babies avoid breathing problems after getting a chest infection called RSV. It compares a medicine called Synagis to no treatment to see if it reduces further breathing issues like wheezing or asthma in their first year.